These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Shaping of an effective immune microenvironment to and by cancer cells. Becht E; Goc J; Germain C; Giraldo NA; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH Cancer Immunol Immunother; 2014 Oct; 63(10):991-7. PubMed ID: 25112529 [TBL] [Abstract][Full Text] [Related]
7. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535 [TBL] [Abstract][Full Text] [Related]
8. Targeting the tumor microenvironment by immunotherapy: part 2. Leibovici J; Itzhaki O; Huszar M; Sinai J Immunotherapy; 2011 Nov; 3(11):1385-408. PubMed ID: 22053888 [TBL] [Abstract][Full Text] [Related]
9. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. Schneider T; Kimpfler S; Warth A; Schnabel PA; Dienemann H; Schadendorf D; Hoffmann H; Umansky V J Thorac Oncol; 2011 Mar; 6(3):432-8. PubMed ID: 21258248 [TBL] [Abstract][Full Text] [Related]
10. The Role of Tumor Microenvironment in Cancer Immunotherapy. Frankel T; Lanfranca MP; Zou W Adv Exp Med Biol; 2017; 1036():51-64. PubMed ID: 29275464 [TBL] [Abstract][Full Text] [Related]
11. Targeting the tumor microenvironment to enhance antitumor immune responses. Van der Jeught K; Bialkowski L; Daszkiewicz L; Broos K; Goyvaerts C; Renmans D; Van Lint S; Heirman C; Thielemans K; Breckpot K Oncotarget; 2015 Jan; 6(3):1359-81. PubMed ID: 25682197 [TBL] [Abstract][Full Text] [Related]
12. Mast cells as targets for immunotherapy of solid tumors. Oldford SA; Marshall JS Mol Immunol; 2015 Jan; 63(1):113-24. PubMed ID: 24698842 [TBL] [Abstract][Full Text] [Related]
13. Disentangling the relationship between tumor genetic programs and immune responsiveness. Bedognetti D; Hendrickx W; Ceccarelli M; Miller LD; Seliger B Curr Opin Immunol; 2016 Apr; 39():150-8. PubMed ID: 26967649 [TBL] [Abstract][Full Text] [Related]
14. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development. Olson DJ; Luke JJ Immunotherapy; 2019 Feb; 11(3):155-159. PubMed ID: 30730272 [No Abstract] [Full Text] [Related]
15. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Gajewski TF; Woo SR; Zha Y; Spaapen R; Zheng Y; Corrales L; Spranger S Curr Opin Immunol; 2013 Apr; 25(2):268-76. PubMed ID: 23579075 [TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-Based Phototriggered Cancer Immunotherapy and Its Domino Effect in the Tumor Microenvironment. Rajendrakumar SK; Uthaman S; Cho CS; Park IK Biomacromolecules; 2018 Jun; 19(6):1869-1887. PubMed ID: 29677439 [TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy. Musetti S; Huang L ACS Nano; 2018 Dec; 12(12):11740-11755. PubMed ID: 30508378 [TBL] [Abstract][Full Text] [Related]
18. Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment. Vasaturo A; Verdoes M; de Vries J; Torensma R; Figdor CG Immunobiology; 2015 Feb; 220(2):243-8. PubMed ID: 25466585 [TBL] [Abstract][Full Text] [Related]
20. Tumor-draining lymph nodes: At the crossroads of metastasis and immunity. du Bois H; Heim TA; Lund AW Sci Immunol; 2021 Sep; 6(63):eabg3551. PubMed ID: 34516744 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]